Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer

Sang Joon Shin, Hei Cheul Jeung, Joong Bae Ahn, Hye Jin Choi, ByoungChul Cho, SunYoung Rha, Nae Choon Yoo, Jae Kyung Roh, Hyuncheol Chung

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Purpose: The aim of this study was to evaluate the activity and the safety of a combination regimen of capecitabine and doxorubicin as salvage chemotherapy in advanced gastric cancer patients who had undergone one or two prior chemotherapy regimens. Methods: Patients received capecitabine, 2,500 mg/m 2/day PO for 14 days (D1-14) and doxorubicin, 30 mg/m2 IV on day 1 every 3 weeks until disease progression. The response was evaluated according to RECIST criteria, and the toxicity was evaluated by NCI-CTC (version 2.0). Results: Forty-five patients were enrolled. Twenty-six patients were treated as second-line chemotherapy and the remaining patients as third-line chemotherapy. A total of 152 cycles of chemotherapy (median 2, range 1-12) were administered. Median dose intensities of capecitabine and doxorubicin were 11,326 and 9.6 mg/m2/week, respectively. The overall response rate was 6.7% (95% CI, 4.1-12.5%) and the disease control rate was 46.7% (95% CI, 28.6-87.1%) according to an intent-to-treat analysis. The median progression-free survival was 11.3 weeks (95% CI, 5.6-16.7 weeks). The median overall survival was 29.1 weeks (95% CI, 18.3-39.9 weeks) with one-year survival rate of 24%. Severe (grade III/IV) hematologic and non-hematologic toxicity was uncommon and included nausea/vomiting in five (11.1%), neutropenia in two (4.4%), anemia in one (2.2%), and hand-foot syndrome in one patient (2.2%). Conclusions: The combination of capecitabine and doxorubicin is a feasible salvage regimen in advanced pre-treated gastric cancer.

Original languageEnglish
Pages (from-to)157-165
Number of pages9
JournalCancer Chemotherapy and Pharmacology
Volume61
Issue number1
DOIs
Publication statusPublished - 2008 Jan 1

Fingerprint

Salvaging
Salvage Therapy
Chemotherapy
Combination Drug Therapy
Doxorubicin
Stomach Neoplasms
Drug Therapy
Toxicity
Disease control
Hand-Foot Syndrome
Neutropenia
Nausea
Disease-Free Survival
Vomiting
Disease Progression
Capecitabine
Anemia
Survival Rate
Safety
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Shin, Sang Joon ; Jeung, Hei Cheul ; Ahn, Joong Bae ; Choi, Hye Jin ; Cho, ByoungChul ; Rha, SunYoung ; Yoo, Nae Choon ; Roh, Jae Kyung ; Chung, Hyuncheol. / Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer. In: Cancer Chemotherapy and Pharmacology. 2008 ; Vol. 61, No. 1. pp. 157-165.
@article{44fa7d47e5bd46b5afbf8a434d1518fb,
title = "Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer",
abstract = "Purpose: The aim of this study was to evaluate the activity and the safety of a combination regimen of capecitabine and doxorubicin as salvage chemotherapy in advanced gastric cancer patients who had undergone one or two prior chemotherapy regimens. Methods: Patients received capecitabine, 2,500 mg/m 2/day PO for 14 days (D1-14) and doxorubicin, 30 mg/m2 IV on day 1 every 3 weeks until disease progression. The response was evaluated according to RECIST criteria, and the toxicity was evaluated by NCI-CTC (version 2.0). Results: Forty-five patients were enrolled. Twenty-six patients were treated as second-line chemotherapy and the remaining patients as third-line chemotherapy. A total of 152 cycles of chemotherapy (median 2, range 1-12) were administered. Median dose intensities of capecitabine and doxorubicin were 11,326 and 9.6 mg/m2/week, respectively. The overall response rate was 6.7{\%} (95{\%} CI, 4.1-12.5{\%}) and the disease control rate was 46.7{\%} (95{\%} CI, 28.6-87.1{\%}) according to an intent-to-treat analysis. The median progression-free survival was 11.3 weeks (95{\%} CI, 5.6-16.7 weeks). The median overall survival was 29.1 weeks (95{\%} CI, 18.3-39.9 weeks) with one-year survival rate of 24{\%}. Severe (grade III/IV) hematologic and non-hematologic toxicity was uncommon and included nausea/vomiting in five (11.1{\%}), neutropenia in two (4.4{\%}), anemia in one (2.2{\%}), and hand-foot syndrome in one patient (2.2{\%}). Conclusions: The combination of capecitabine and doxorubicin is a feasible salvage regimen in advanced pre-treated gastric cancer.",
author = "Shin, {Sang Joon} and Jeung, {Hei Cheul} and Ahn, {Joong Bae} and Choi, {Hye Jin} and ByoungChul Cho and SunYoung Rha and Yoo, {Nae Choon} and Roh, {Jae Kyung} and Hyuncheol Chung",
year = "2008",
month = "1",
day = "1",
doi = "10.1007/s00280-007-0470-3",
language = "English",
volume = "61",
pages = "157--165",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "1",

}

Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer. / Shin, Sang Joon; Jeung, Hei Cheul; Ahn, Joong Bae; Choi, Hye Jin; Cho, ByoungChul; Rha, SunYoung; Yoo, Nae Choon; Roh, Jae Kyung; Chung, Hyuncheol.

In: Cancer Chemotherapy and Pharmacology, Vol. 61, No. 1, 01.01.2008, p. 157-165.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer

AU - Shin, Sang Joon

AU - Jeung, Hei Cheul

AU - Ahn, Joong Bae

AU - Choi, Hye Jin

AU - Cho, ByoungChul

AU - Rha, SunYoung

AU - Yoo, Nae Choon

AU - Roh, Jae Kyung

AU - Chung, Hyuncheol

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Purpose: The aim of this study was to evaluate the activity and the safety of a combination regimen of capecitabine and doxorubicin as salvage chemotherapy in advanced gastric cancer patients who had undergone one or two prior chemotherapy regimens. Methods: Patients received capecitabine, 2,500 mg/m 2/day PO for 14 days (D1-14) and doxorubicin, 30 mg/m2 IV on day 1 every 3 weeks until disease progression. The response was evaluated according to RECIST criteria, and the toxicity was evaluated by NCI-CTC (version 2.0). Results: Forty-five patients were enrolled. Twenty-six patients were treated as second-line chemotherapy and the remaining patients as third-line chemotherapy. A total of 152 cycles of chemotherapy (median 2, range 1-12) were administered. Median dose intensities of capecitabine and doxorubicin were 11,326 and 9.6 mg/m2/week, respectively. The overall response rate was 6.7% (95% CI, 4.1-12.5%) and the disease control rate was 46.7% (95% CI, 28.6-87.1%) according to an intent-to-treat analysis. The median progression-free survival was 11.3 weeks (95% CI, 5.6-16.7 weeks). The median overall survival was 29.1 weeks (95% CI, 18.3-39.9 weeks) with one-year survival rate of 24%. Severe (grade III/IV) hematologic and non-hematologic toxicity was uncommon and included nausea/vomiting in five (11.1%), neutropenia in two (4.4%), anemia in one (2.2%), and hand-foot syndrome in one patient (2.2%). Conclusions: The combination of capecitabine and doxorubicin is a feasible salvage regimen in advanced pre-treated gastric cancer.

AB - Purpose: The aim of this study was to evaluate the activity and the safety of a combination regimen of capecitabine and doxorubicin as salvage chemotherapy in advanced gastric cancer patients who had undergone one or two prior chemotherapy regimens. Methods: Patients received capecitabine, 2,500 mg/m 2/day PO for 14 days (D1-14) and doxorubicin, 30 mg/m2 IV on day 1 every 3 weeks until disease progression. The response was evaluated according to RECIST criteria, and the toxicity was evaluated by NCI-CTC (version 2.0). Results: Forty-five patients were enrolled. Twenty-six patients were treated as second-line chemotherapy and the remaining patients as third-line chemotherapy. A total of 152 cycles of chemotherapy (median 2, range 1-12) were administered. Median dose intensities of capecitabine and doxorubicin were 11,326 and 9.6 mg/m2/week, respectively. The overall response rate was 6.7% (95% CI, 4.1-12.5%) and the disease control rate was 46.7% (95% CI, 28.6-87.1%) according to an intent-to-treat analysis. The median progression-free survival was 11.3 weeks (95% CI, 5.6-16.7 weeks). The median overall survival was 29.1 weeks (95% CI, 18.3-39.9 weeks) with one-year survival rate of 24%. Severe (grade III/IV) hematologic and non-hematologic toxicity was uncommon and included nausea/vomiting in five (11.1%), neutropenia in two (4.4%), anemia in one (2.2%), and hand-foot syndrome in one patient (2.2%). Conclusions: The combination of capecitabine and doxorubicin is a feasible salvage regimen in advanced pre-treated gastric cancer.

UR - http://www.scopus.com/inward/record.url?scp=34848825963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848825963&partnerID=8YFLogxK

U2 - 10.1007/s00280-007-0470-3

DO - 10.1007/s00280-007-0470-3

M3 - Article

C2 - 17426971

AN - SCOPUS:34848825963

VL - 61

SP - 157

EP - 165

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 1

ER -